The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.
An article from
Emerging biotech
The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.
Published July 14, 2026
Draig Therapeutics raised a $65 million Series B round on July 14, 2026.
Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Chai Discovery raises $400M as AI drug discovery booms
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
Drug Farm Completes First Closing of $55 Million Series D Financing to Advance Clinical and Preclinical Development Pipeline
Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA…
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of…
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and…
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and…
HMNC Brain Health has secured $50 million in a Series B fundraise designed to support two psychiatry programs into mid-stage…
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
